SCHEDULE: Armistice Capital Discloses Stake in Biodexa Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Biodexa Pharmaceuticals Plc's American Depositary Shares.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed a Schedule 13G, indicating their beneficial ownership of 187,975 American Depositary Shares (ADS) of Biodexa Pharmaceuticals Plc.
• This holding represents 9.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The filing is an amendment to a previous filing, with the event date requiring this statement being March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on ownership changes and does not contain operational or financial performance updates for Biodexa Pharmaceuticals Plc.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant stake (9.99%) in Biodexa Pharmaceuticals Plc, which could signal confidence or strategic interest in the company.
• The filing indicates shared voting and dispositive power over 187,975 shares, suggesting active management of the investment.

Negatives

• The filing does not provide details on the specific reasons for acquiring this stake, leaving the strategic intent open to interpretation.
• The Master Fund, the direct holder, disclaims beneficial ownership due to the investment management agreement, which could complicate direct control attribution.

Risks

• The concentration of 9.99% ownership by a single entity could lead to increased volatility if that entity decides to divest its holdings.
• As an investment manager, Armistice Capital's investment decisions are subject to market conditions and fund performance, which could impact their holdings in Biodexa Pharmaceuticals.

Future Outlook

The filing does not contain forward-looking statements or specific future guidance from Biodexa Pharmaceuticals Plc. It solely reports on the ownership stake of Armistice Capital, LLC and Steven Boyd.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake disclosures by investment firms like Armistice Capital often precede or coincide with periods of increased investor scrutiny or potential strategic shifts within the biotechnology sector, particularly for companies like Biodexa Pharmaceuticals that may be undergoing development or seeking market positioning.

Stakeholder Impact

• Shareholders: May see increased trading activity or potential shifts in share price due to the significant stake held by Armistice Capital, LLC.
• Management of Biodexa Pharmaceuticals Plc: May need to engage with Armistice Capital, LLC regarding their investment strategy and the company's future direction.

Next Steps

• Monitor future filings from Armistice Capital, LLC and Steven Boyd for any changes in their beneficial ownership of Biodexa Pharmaceuticals Plc.
• Observe Biodexa Pharmaceuticals Plc's strategic communications for any potential impact or response to this increased investor interest.

Key Dates

Keywords

Biodexa Pharmaceuticals, Schedule 13G, Armistice Capital, Steven Boyd, American Depositary Shares, Beneficial Ownership, SEC Filing, Investment Management